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INTRODUCTION
Bone tissue engineering has been an increasing field of research during the last years. The ideal approach for a regenerative application would consist in the use 
of cells from the patient, scaffolding materials and differentiation growth factors. Bone morphogenetic protein-2 (BMP-2) is one such growth factors with a strong 
ability to induce new bone and cartilage formation and has been used as a powerful osteoinductive component of several late-stage tissue engineering products for 
bone grafting. In this work, we aimed at obtaining high yields of human recombinant BMP-2 in a stable, pure and biologically active form by use of a new bacteria 
expression system that circumvents the disadvantages of conventional recombinant protein preparation methods and to perform a study of the stability conditions 
and the functionality of these peptides in vitro in human mesenchymal stem cells and C2C12 murine cell line.  
CONCLUSIONS
Ø The novel approach described herein shows to be a promising way for 
obtaining large amounts of partially purified rhBMP-2 which shows evidence of 
bioactivity, capable of inducing some markers of specific osteogenic (bone) 
differentiation and showing no relevant cytotoxicity.
MATERIALS & METHODS
Fig. 1. The sequence coding for mature rhBMP-2 was cloned in a pET-25b vector and 
expressed in BL21DE3 E. coli strain. This vector permitted expression of recombinant 
protein into periplasm where ambient is permissive to the formation of cysteine bridges of 
folded protein. 
rhBMP-2 was then purified by high affinity chromatography and size 
exclusion chromatography and tested in C2C12 cell line. This is a 
well-studied and stable model for testing the in vitro biological activity 
of recombinant BMPs.
RESULTS & DISCUSSION
Purification by size exclusion chromatography
Biological activity assays
Fig. 3. A) Silver stained reduced SDS-PAGE reveals 
purification growth factor to up 95%. B) Non-reduced
western-blot permitted observe monomer, dimer and 
polymer fractions. BMP-2 is at pH 8-10. An antibody 
against the 6x histidine tag was used. 
Fig. 4. Size exclusion chromatography permitted partial separation of 
monomer, dimer and polymer fractions, as analysed by Western-blot. 
Conformations change with pH, buffer and concentration of growth factor.
Purification of rhBMP-2 by HPLC
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Two variants of rhBMP-2 were 
produced: variant I containing two 
adjacent sites for protease cleavage in 
order to eliminate plasmid tags and 
variant II containing the protein with no 
additional cleavage sites.
Fig. 7. Addition of 5-500ng/ml rhBMP-2 to human 
adipose mesenchymal stem cells resulted in 
changes of morphology. 10 days of cell culture.
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Fig. 2. Expression of recombinant bacteria was performed 
in a fermentor allowing large yields of rhBMP-2, around 
110mg/L.
For future bone biomedical applications!
Fig. 5. MTS bioassay revealed no 
significant cytotoxicity of purified rhBMP-2
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Fig. 6. ALP bioassay revealed an 
increase in ALP levels with continuous  
purified 5-500ng/ml rhBMP-2 stimulation
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Fig. 10. RT-PCR shows increase of specific 
markers of osteogenic differentiation (ALP, 
Smad-5, Smad-1, Runx2) when C2C12 cells 
were stimulated with 500ng/ml of our rhBMP-2  
stabilized at pH 10. 5 days of cell culture
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Fig. 8. von Kossa bioassay performed in 
mesenchymal stem cells from bone marrow 
after continuous stimulation with 500ng/ml
purified rhBMP-2 shows evidence of nodule 
formation. 14 days of cell culture
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Table 1. Effect of L-arginine in 
the solubilization of rhBMP-2
A B
A) Effect of 
[BMP-2]
B) Effect of pH 
and 
[arginine]
0 ng/ml 500 ng/ml
Fig. 9.  Effect of rhBMP-2 added to C2C12 after 5 
days of cell culture. Changes in morphology are 
observed but not similar to positive control. With 
heparin changes are more towards osteoblast-like.
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